The molecular classification of BC plays a crucial role in facilitating precise diagnosis, selecting appropriate treatments, and accurately predicting prognosis, especially in the context of hormonal and anti-HER2-targeted therapies [1]. This evidence concerns the gene ERBB2 and breast cancer.